Impact of Age and Comorbidities on the Treatment of Gastrointestinal Malignancies

Seminars in Radiation Oncology

Volumn 22, Issue 4, 2012, Pages 311-320

  Wo, Jennifer Y ^a   Hong, Theodore S ^a   Kachnic, Lisa A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANOREXIA; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COLORECTAL CANCER; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM RESECTION; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; COMORBIDITY; DECISION MAKING; GASTROINTESTINAL NEOPLASMS; GERIATRIC ASSESSMENT; HUMANS; PATIENT SELECTION; QUALITY OF LIFE; RISK FACTORS;

EID: 84866321561     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.05.008     Document Type: Review

References (80)

1. Yancik R., Ries L.A. Cancer in older persons: An international issue in an aging world. Semin Oncol 2004, 31:128-136.
2. Castellón T.D., Sieving K.E. An experimental test of matrix permeability and corridor use by an endemic understory bird. Conserv Biol 2006, 20:135-145.
3. Yee K.W., Pater J.L., Pho L., et al. Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier?. J Clin Oncol 2003, 21:1618-1623.
4. Aapro M.S., Köhne C.H., Cohen H.J., et al. Never too old?. Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005, 10:198-204.
5. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
6. Kahn K.L., Adams J.L., Weeks J.C., et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010, 303:1037-1045.
7. Schrag D., Rifas-Shiman S., Saltz L., et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002, 20:3999-4005.
8. Neugut A.I., Matasar M., Wang X., et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006, 24:2368-2375.
9. Gross C.P., McAvay G.J., Guo Z., et al. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 2007, 109:2410-2419.
10. Birkmeyer J.D., Stukel T.A., Siewers A.E., et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003, 349:2117-2127.
11. Steyerberg E.W., Neville B.A., Koppert L.B., et al. Surgical mortality in patients with esophageal cancer: Development and validation of a simple risk score. J Clin Oncol 2006, 24:4277-4284.
12. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007, 8:226-234.
13. Sjoquist K.M., Burmeister B.H., Smithers B.M., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011, 12:681-692.
14. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
15. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
16. Abrams J.A., Buono D.L., Strauss J., et al. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer 2009, 115:4924-4933.
17. Minsky B.D., Neuberg D., Kelsen D.P., et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999, 43:517-523.
18. Ohtsu A., Boku N., Muro K., et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999, 17:2915-2921.
19. Michel P., Adenis A., Di Fiore F., et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: Multicenter phase II FFCD trial. Br J Cancer 2006, 95:705-709.
20. Coia L.R., Minsky B.D., Berkey B.A., et al. Outcome of patients receiving radiation for cancer of the esophagus: Results of the 1992-1994 Patterns of Care Study. J Clin Oncol 2000, 18:455-462.
21. Coia L.R., Engstrom P.F., Paul A.R., et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991, 20:29-36.
22. Anderson S.E., Minsky B.D., Bains M., et al. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 2007, 96:1823-1827.
23. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593-1598.
24. Servagi-Vernat S., Bosset M., Crehange G., et al. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or = 75 years: A prospective, single-arm phase II study. Drugs Aging 2009, 26:255-262.
25. Ajani J.A., Walsh G., Komaki R., et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004, 100:2347-2354.
26. Mak R.H., Mamon H.J., Ryan D.P., et al. Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Dis Esophagus 2010, 23:316-323.
27. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337:161-167.
28. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
29. Tougeron D., Di Fiore F., Thureau S., et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008, 99:1586-1592.
30. Ruol A., Portale G., Castoro C., et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol 2007, 14:3243-3250.
31. Urschel J.D., Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003, 185:538-543.
32. Kaklamanos I.G., Walker G.R., Ferry K., et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 2003, 10:754-761.
33. Rice D.C., Correa A.M., Vaporciyan A.A., et al. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg 2005, 79:391-397. discussion 391-397.
34. Fogh S.E., Yu A., Kubicek G.J., et al. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy?. Int J Radiat Oncol Biol Phys 2011, 80:1372-1376.
35. Smith G.L., Smith B.D., Buchholz T.A., et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 2009, 74:482-489.
36. SEER Cancer Statistics Review 1975-2005, Based on November 2007 SEER data submission, posted to the SEER Web site, 2008. http://seer.cancer.gov/csr/1975-2005/, L. Ries, M. Krapcho, D.G. Stinchcomb (Eds.).
37. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710.
38. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-An Eastern Cooperative Oncology Group study. J Clin Oncol 1985, 3:373-378.
39. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002, 53:146-150.
40. Fernández-del Castillo C., Rattner D.W., Warshaw A.L. Standards for pancreatic resection in the 1990s. Arch Surg 1995, 130:295-299. discussion 299-300.
41. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995, 221:721-731. discussion 731-733.
42. Fong Y., Blumgart L.H., Fortner J.G., et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995, 222:426-434. discussion 434-437.
43. Kayahara M., Nagakawa T., Ueno K., et al. Pancreatic resection for periampullary carcinoma in the elderly. Surg Today 1994, 24:229-233.
44. Hannoun L., Christophe M., Ribeiro J., et al. A report of forty-four instances of pancreaticoduodenal resection in patients more than seventy years of age. Surg Gynecol Obstet 1993, 177:556-560.
45. Spencer M.P., Sarr M.G., Nagorney D.M. Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified?. Ann Surg 1990, 212:140-143.
46. Barnett S.A., Collier N.A. Pancreaticoduodenectomy: Does preoperative biliary drainage, method of pancreatic reconstruction or age influence perioperative outcome?. A retrospective study of 104 consecutive cases. A N Z J Surg 2006, 76:563-568.
47. Bilimoria K.Y., Bentrem D.J., Ko C.Y., et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007, 246:173-180.
48. Brennan M.F., Kattan M.W., Klimstra D., et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004, 240:293-298.
49. Sohn T.A., Yeo C.J., Cameron J.L., et al. Should pancreaticoduodenectomy be performed in octogenarians?. J Gastrointest Surg 1998, 2:207-216.
50. Tani M., Kawai M., Hirono S., et al. A pancreaticoduodenectomy is acceptable for periampullary tumors in the elderly, even in patients over 80 years of age. J Hepato Biliary Pancreat Surg 2009, 16:675-680.
51. Miyamoto D.T., Mamon H.J., Ryan D.P., et al. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys 2010, 77:1171-1177.
52. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782. discussion 782-784.
53. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007, 297:267-277.
54. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008, 299:1019-1026.
55. Horowitz D.P., Hsu C.C., Wang J., et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2011, 80:1391-1397.
56. Krzyzanowska M.K., Earle C.C., Kuntz K.M., et al. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 67:211-218.
57. Matsumoto K., Miyake Y., Kato H., et al. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Digestion 2011, 84:230-235.
58. Hentic O., Dreyer C., Rebours V., et al. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol 2011, 17:3497-3502.
59. Maréchal R., Demols A., Gay F., et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008, 36:e16-e21.
60. Locher C., Fabre-Guillevin E., Brunetti F., et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: An observational study. Crit Rev Oncol Hematol 2008, 68:178-182.
61. Vickers M.M., Powell E.D., Asmis T.R., et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer-Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 2012, 48(10):1434-1442.
62. Nakai Y., Isayama H., Sasaki T., et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol 2011, 78:252-259.
63. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
64. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
65. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
66. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27:5124-5130.
67. Dobie S.A., Warren J.L., Matthews B., et al. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112:789-799.
68. Rutten H., den Dulk M., Lemmens V., et al. Survival of elderly rectal cancer patients not improved: Analysis of population based data on the impact of TME surgery. Eur J Cancer 2007, 43:2295-2300.
69. Chessin D.B., Enker W., Cohen A.M., et al. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: A 14-year experience from a specialty service. J Am Coll Surg 2005, 200:876-882. discussion 882-884.
70. Habr-Gama A., Perez R.O., Nadalin W., et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005, 9:90-99. discussion 99-101.
71. Vulto A.J., Lemmens V.E., Louwman M.W., et al. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer 2006, 106:2734-2742.
72. Schrag D., Gelfand S.E., Bach P.B., et al. Who gets adjuvant treatment for stage II and III rectal cancer?. Insight from surveillance, epidemiology, and end results-Medicare. J Clin Oncol 2001, 19:3712-3718.
73. Margalit D.N., Mamon H.J., Ancukiewicz M., et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys 2011, Epub 2011 Mar 4.
74. Pasetto L.M., Friso M.L., Pucciarelli S., et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res 2006, 26:3913-3923.
75. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: Report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24.
76. Ngan S., Fisher R., Goldstein D., et al. A randomized trial comparing local recurrence (LR) rates between short-course. (SC) and long course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An Intergroup Trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol 2010, 28(15s):3509. Abstr 3509.
77. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
78. André T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
79. McCleary N.J., Meyerhardt J., Green E. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/IIII colon cancer. Findings from the ACCENT database. J Clin Oncol 2009, 27:170s.
80. McCleary N.J. Treatment considerations in elderly colorectal cancer patients. Clin Adv Hematol Oncol 2010, 8:337-339.